毕建斌：PSA筛查为前列腺癌筑牢“早”防线

Core Insights - The five-year survival rate for prostate cancer patients in China is approximately 70%, significantly lower than over 97% in developed countries, highlighting the need for early screening to improve outcomes [1][2] - Prostate cancer is a major health burden for men in China, with around 134,000 new cases and 48,000 deaths reported in 2022, indicating a rising trend in incidence and mortality due to an aging population [1][2] - The "China Prostate Cancer Screening Research Report" emphasizes the effectiveness of PSA testing in early detection and improving patient prognosis, advocating for standardized screening practices [1][3] Screening Recommendations - Men over 50 are advised to undergo annual PSA screening, as early detection is crucial for improving survival rates and treatment outcomes [2][3] - Symptoms such as urinary difficulties should prompt immediate medical attention, as many patients are diagnosed at advanced stages due to a lack of awareness and stigma surrounding the disease [2][3] Importance of Early Detection - Early screening is identified as a key starting point for comprehensive management of prostate cancer, significantly enhancing early diagnosis and treatment, which can lead to better survival rates and quality of life [3][4] - The financial burden of late-stage treatment is considerably higher, making early detection not only a health priority but also a cost-effective strategy for healthcare systems [3][4]